1. Kesisoglou, F., Balakrishnan, A. & Manser, K. Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption. J. Pharm. Sci. 105, 722–728 (2016).
2. Kesisoglou, F. et al. Suitability of a minipig model in assessing clinical bioperformance of matrix and multiparticulate extended-release formulations for a bcs class III drug development candidate. J. Pharm. Sci. 103, 636–642 (2014).
3. Abrahamsson, B. & Soderlind, E. Modified-Release Dosage Forms: Formulation Screening in the Pharmaceutical Industry. in Oral Drug Absorption 281–353 (CRC Press, 2016). doi:10.3109/9781420077346-15.
4. Zhou, H. & Seitz, K. In Vivo Evaluation of Oral Dosage Form Performance. in Developing Solid Oral Dosage Forms 365–378 (Academic Press, 2009). doi:10.1016/B978-0-444-53242-8.00016-3.
5. Dressman, J. B. & Yamada, K. Animal models for oral drug absorption. in Pharmaceutical Bioequivalence 235–266 (Marcel Dekker, New York, 1991).
6. Muth, E. A. et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 35, 4493–4497 (1986).
7. Food and Drug Administration, NDA 20-699/S-029. 1–28 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/020699_S029_EFFEXOR_AP.pdf (2002).
8. Parsons, A. T., Anthony, R. M. & Meeker, J. E. Two fatal cases of venlafaxine poisoning. J. Anal. Toxicol. 20, 266–268 (1996).
9. Magalhães, P., Alves, G., Llerena, A. & Falcão, A. Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers. Drug Metabol. Drug Interact. 29, 129–141 (2014).
10. Food and Drug Administration, Original NDA and Original BLA Approvals, December 1993, Effexor NDA #020151, Approval Date: 12/28/1993. 1–2 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process&rptName=2&reportSelectMonth=12&reportSelectYear=1993&nav (1993).
11. Food and Drug Administration, All Approvals and Tentative Approvals, October 1997, Effexor XR NDA #020699, Approval Date: 10/20/1997. 1–21 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process (1997).
12. Muth, E. A., Moyer, J. A., Haskins, J. T., Andree, T. H. & Husbands, G. E. M. Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev. Res. 23, 191–199 (1991).
13. Klamerus, K. J. et al. Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl Metabolite. J. Clin. Pharmacol. 32, 716–724 (1992).
14. Lessard, E. et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9, 435–43 (1999).
15. Fukuda, T. et al. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br. J. Clin. Pharmacol. 47, 450–453 (1999).
16. Barman Balfour, J. A. & Jarvis, B. Venlafaxine extended-release: A review of its clinical potential in the management of generalised anxiety disorder. CNS Drugs 14, 483–503 (2000).
17. Yardley, J. P. et al. 2-Phenyl-2-(l-hydroxycycloalkyl)ethylamine Derivatives: Synthesis and Antidepressant Activity. J. Med. Chem. 33, 2899–2905 (1990).
18. Howell, S. R., Hicks, D. R., Scatina, J. A. & Sisenwine, S. F. Pharmacokinetics of venlafaxine and o-desmethylvenlafaxine in laboratory animals. Xenobiotica 24, 315–327 (1994).
19. Holliday, S. M. & Benfield, P. Venlafaxine: A Review of its Pharmacology and Therapeutic Potential in Depression. Drugs 49, 280–294 (1995).
20. Yardley, J. P. & Asselin, A. A. Enantiomers of O-desmethyl venlafaxine. 1–8 (2003).
21. Pfizer Australia, PRODUCT INFORMATION, EFEXOR-XR venlafaxine (as hydrochloride), Amendment June 11, 2013,. https://www.pfizer.com.au/sites/pfizer.com.au/files/g10005016/f/201311/PI_EfexorXr_310.pdf (2013).
22. Howell, S. R., Husbands, G. E. M., Scatina, J. A. & Sisenwine, S. F. Metabolic disposition of 14c-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 23, 349–359 (1993).
23. Paul Wang, C., Howell, S. R., Scatina, J. & Sisenwine, S. F. The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine. Chirality 4, 84–90 (1992).
24. Hicks, H. R., Wolaniuk, D., Russell, A., Nancy, C. & Kraml, M. A high-performance liquid chromatographic method for the simultaneous determination of venlafaxine and o-desmethylvenlafaxine in biological fluids. Ther. Drug Monit. 16, 100–107 (1994).
25. Da Fonseca, P. & Bonato, P. S. Chiral HPLC analysis of venlafaxine metabolites in rat liver microsomal preparations after LPME extraction and application to an in vitro biotransformation study. in Analytical and Bioanalytical Chemistry vol. 396 817–824 (Anal Bioanal Chem, 2010).
26. Zhang, S. et al. Engineering hot-melt extruded solid dispersion for controlled release of hydrophilic drugs. Eur. J. Pharm. Sci. 100, 109–115 (2017).
27. Jia, E. & Bartlett, M. G. Recent advances in liquid chromatographic methods for the determination of selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors. Biomedical Chromatography vol. 34 e4760 (2020).
28. Shah, G. R., Thaker, B. T., Surati, K. R. & Parabia, M. H. Simultaneous determination of venlafaxine and its main active metabolite O-desmethyl venlafaxine in rat plasma by LC-MS/MS. Anal. Sci. 25, 1207–1210 (2009).
29. Ahmad, S. et al. Solid phase extraction and LC-MS/MS method for quantification of venlafaxine and its active metabolite O-desmethyl venlafaxine in rat plasma. J. Chil. Chem. Soc. 61, 3130–3135 (2016).
30. Aryal, B., Aryal, D., Kim, E. J. & Kim, H. G. Pharmacokinetics of venlafaxine and its major metabolite o-desmethylvenlafaxine in freely moving mice using automated dosing/sampling system. Indian J. Pharmacol. 44, 20–25 (2012).
31. Da Fonseca, P. & Bonato, P. S. Hollow-fiber liquid-phase microextraction and chiral LC-MS/MS analysis of venlafaxine and its metabolites in plasma. Bioanalysis 5, 721–730 (2013).
32. Zhang, Y. et al. Phenolic esters of O-desmethylvenlafaxine with improved Oral bioavailability and brain uptake. Molecules 18, 14920–14934 (2013).
33. Liu, M. et al. A novel prodrug strategy to improve the oral absorption of O-desmethylvenlafaxine. Exp. Ther. Med. 12, 1611–1617 (2016).
34. Dubey, S. K., Saha, R. N., Jangala, H. & Pasha, S. Rapid sensitive validated UPLC-MS method for determination of venlafaxine and its metabolite in rat plasma: Application to pharmacokinetic study. J. Pharm. Anal. 3, 466–471 (2013).
35. Pan, P. P. et al. Simultaneous Determination of Methadone, Fluoxetine, Venlafaxine and Their Metabolites in Rat Plasma by UPLC–MS/MS for Drug Interaction Study. Chromatographia 79, 601–608 (2016).
36. Gu, G. et al. Validation of an LC-MS/MS method for simultaneous quantification of venlafaxine and its five metabolites in rat plasma and its application in a pharmacokinetic study. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1087–1088, 29–35 (2018).
37. Chen, F. et al. In vitro and in vivo rat model assessments of the effects of vonoprazan on the pharmacokinetics of venlafaxine. Drug Des. Devel. Ther. 14, 4815–4824 (2020).
38. Song, L. et al. Rapid solid-phase extraction coupled with GC–MS method for the determination of venlafaxine in rat plasma: Application to the drug–drug pharmacokinetic interaction study of venlafaxine combined with fluoxetine. J. Sep. Sci. 40, 3462–3468 (2017).
39. Shahnawaz, S., Siddiqui, Z. & Hoda, Q. Sensitive Spectrofluorimetric method of analysis for venlafaxine in spiked rat plasma and formulations. J. Fluoresc. 20, 821–825 (2010).
40. Nerkar, P. P. & Gattan, S. G. Cress seed mucilage based buccal mucoadhesive gel of venlafaxine: In vivo, in vitro evaluation. J. Mater. Sci. Mater. Med. 23, 771–779 (2012).
41. Nerkar, P. P. & Gattani, S. G. Oromucosal delivery of venlafaxine by linseed mucilage based gel: In vitro and in vivo evaluation in rabbits. Arch. Pharm. Res. 36, 846–853 (2013).
42. Peng, Y. et al. Optimization of thermosensitive chitosan hydrogels for the sustained delivery of venlafaxine hydrochloride. Int. J. Pharm. 441, 482–490 (2013).
43. Ali, L. et al. Venlafaxine-loaded sustained-release poly(hydroxyethyl methacrylate-co-itaconic acid) hydrogel composites: their synthesis and in vitro/in vivo attributes. Iran. Polym. J. (English Ed. 28, 251–258 (2019).
44. Sher, M., Ahmad, M., Hassan, F., Naeem-Ul-Hassan, M. & Hussain, M. A. Development and validation of an HPLC-UV method for accelerated stability study and pharmacokinetic analysis of venlafaxine. Brazilian J. Pharm. Sci. 56, 17728 (2020).
45. Rowley, M., Potts, A. & Sims, E. Extended release tablet formulations of venlafaxine. 1–8 (2005).
46. Zhang, X., Gu, X., Wang, X., Wang, H. & Mao, S. Tunable and sustained-release characteristics of venlafaxine hydrochloride from chitosan–carbomer matrix tablets based on in situ formed polyelectrolyte complex film coating. Asian J. Pharm. Sci. 13, 566–574 (2018).
47. Food and Drug Administration, Bioanalytical Method Validation: Guidance for Industry. 1–44 https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf (2018).
48. World Health Organization, Use of anticoagulants in diagnostic laboratory investigations. (2002).